• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biotechnology Progress >Recombinant Lucilia Sericata Chymotrypsin in a Topical Hydrogel Formulation Degrades Human Wound Eschar Ex Vivo
【24h】

Recombinant Lucilia Sericata Chymotrypsin in a Topical Hydrogel Formulation Degrades Human Wound Eschar Ex Vivo

机译：局部水凝胶制剂中的重组Lucilia Sericata胰凝乳蛋白酶可降解人体伤口埃沙尔

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Larval biotherapy is a debridement tool used in wound management. The mechanism of action involves degradation of eschar by serine proteases including chymotrypsin within the alimentary fluids of first instar Lucilia sericata. With the rationale of obviating some limitations of biotherapy, including cost, complexity of use, and patient reticence, the present study describes a mobile hydrogel formulation containing freeze-dried recombinant L. sericata chymotrypsin designed for topical application. Neither freeze-drying nor formulation into the hydrogel significantly attenuated the measured activity of released enzyme compared to fresh-frozen enzyme in aqueous solution. Gel electrophoresis confirmed qualitatively that the chymotrypsin/hydro gel formulation both with and without supplementary urea at 10% w/v degraded human chronic wound eschar ex vivo. Mindful that the hallmark of intractability of chronic wounds is aberrant biochemistry, the pH activity profile for the enzymel hydro gel formulation was compared with exudate pH in chronic wounds of mixed aetiology in a cohort of 48 hospital in-patients. Five patients' wounds were acidic, however, the remainder were predominantly alkaline and coincided with the pH optimum for the insect enzyme. Thus, a recombinant L. sericata chymotrypsin and hydrogel formulation could represent a pragmatic alternative to larval therapy for the management of chronic wounds.
机译：幼虫生物疗法是用于伤口处理的清创工具。作用机理涉及第一龄幼虫Lucilia sericata的消化液中丝氨酸蛋白酶（包括胰凝乳蛋白酶）降解焦char。基于消除生物疗法的一些局限性的基本原理，包括成本，使用的复杂性和患者的沉默，本研究描述了一种移动水凝胶制剂，该制剂包含冻干重组绢丝线虫胰凝乳蛋白酶，设计用于局部应用。与水溶液中的新鲜冷冻酶相比，冷冻干燥和配制成水凝胶都不会显着减弱所测得的释放酶的活性。凝胶电泳定性地证实，在有和没有以10％w / v补充尿素的情况下，胰凝乳蛋白酶/水凝胶制剂均可降解人慢性伤口。考虑到慢性伤口难治性的标志是异常的生化反应，将酶水解凝胶制剂的pH活性曲线与混合病因性慢性伤口的渗出液pH进行了比较，研究对象是48名住院患者。五名患者的伤口是酸性的，但是其余部分主要是碱性的，并且与昆虫酶的最适pH相吻合。因此，重组丝绢乳糜胰凝乳蛋白酶和水凝胶制剂可以代表实用的替代幼虫疗法来治疗慢性伤口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号